touchEXPERT OPINIONS Evolving treatment options beyond progression for HER2-positive advanced breast cancer
Stay up-to-date with the latest data for novel targeted therapies being developed to overcome resistance to standard of care HER2-targeted therapies in patients with HER2-positive advanced breast cancer.
Dr Eva Ciruelos examines why new treatments are required to address unmet needs in patients with HER2-positive advanced breast cancer and describes how novel therapies act to target resistance to anti-HER2 therapies.
1/3 Next InterviewInterview Questions
In this interview, Dr Eva Ciruelos answers the following questions:
- What is the clinical rationale for the use of anti-HER2 therapies beyond progression?
- How does resistance to current anti-HER2 therapies develop?
- What is the rationale for the development of antibody-drug conjugates for HER2-positive breast cancer?
- How are novel tyrosine kinase inhibitors being used to target HER2-positive breast cancer?
- How might novel monoclonal antibodies enhance antibody-dependent cellular cytotoxicity in HER2-positive breast cancer?
About Dr Eva Ciruelos
Eva M Ciruelos, MD, PhD, is a medical oncologist and coordinator of the Multidisciplinary Breast Cancer Units at the University Hospital 12 de Octubre and HM Hospitals in Madrid, Spain. In addition, she has been an Associate Professor in the Department of Medicine at the Complutense University of Madrid since 2008. read more
Dr Ciruelos is the principal investigator of several clinical trials and research projects in breast cancer and is on the steering committee for several registration clinical trials. She is the current vice president of the Solid Tumor Intensification (SOLTI) Group and is also a member of the scientific committee of the Breast International Group (BIG) and the St Gallen Conference Panel. Dr Ciruelos is an author and reviewer of oncology practice guidelines at both a national (Spanish Society of Medical Oncology) and international level.
She has contributed to oncology textbook chapters, and is an author or co-author of articles with a focus on breast cancer research. She also plays an active role in medical education events for breast cancer.
Disclosures:
Consultant/advisory board fees and congress assistance from Eli Lilly, Novartis, Pfizer and Roche.
Prof. Rupert Bartsch reviews the latest efficacy and safety data for later-line novel HER2-targeted therapies in patients with HER2-positive advanced breast cancer.
2/3 Next InterviewInterview Questions
In this interview, Prof. Rupert Bartsch answers the following questions:
- Which key clinical trials investigating novel anti-HER2 therapies are of interest?
- What were the main outcomes from the HER2CLIMB study of the tucatinib combination?
- What do the results from the DESTINY-Breast01 study tell us about the effectiveness of trastuzumab deruxtecan?
- What were the main outcomes of the SOPHIA trial in patients treated with margetuximab?
- What do these trials add to outcomes observed in clinical trials with other targeted agents such as neratinib?
About Prof. Rupert Bartsch
Rupert Bartsch, MD, is Associate Professor of Medicine at the Medical University of Vienna, Austria, and currently serves as Director of the Breast Cancer Program at the Department of Oncology. Prior to this, he was Head of the Breast Centre at the Elisabethinen Hospital in Linz, Austria, and from late 2017 until March 2018, he was based at the German Breast Group in Neu-Isenburg, Germany. read more
Prof. Bartsch has a longstanding clinical and scientific focus on breast cancer. Together with his colleagues, he has published over 150 articles in peer-reviewed journals, among them Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Lancet Oncology.
Disclosures:
Grant/research support from Daiichi Sankyo, Novartis and Roche; Honoraria from Accord Healthcare, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Novartis, Pfizer, Roche and Sandoz; Advisory Board fees from AstraZeneca, Celgene; Daiichi Sankyo, Eisai, Eli Lilly, MSD, Novartis, Roche and Samsung.
Prof. Sibylle Loibl discusses how novel treatment options may influence the future clinical management of patients with HER2-positive advanced breast cancer.
3/3 Take CME TestInterview Questions
In this interview, Prof. Sibylle Loibl answers the following questions:
- With data emerging for the novel therapies tucatinib, trastuzumab deruxtecan and neratinib, how might these impact current practice?
- What are the key treatment-emergent adverse events experienced with these agents and how might they impact uptake in clinical practice?
- What patient- and/or disease-related characteristics impact the choice of treatment?
- How might ongoing phase III trials in HER2-positive advanced breast cancer impact patient management in the future?
About Prof. Sibylle Loibl
Sibylle Loibl, MD, PhD, is Chief Executive Officer and Chair of the German Breast Group (GBG), one of the leading study groups for breast cancer worldwide. She devotes the majority of her time to clinical trial research at the GBG and at her clinical affiliations – the University of Frankfurt and Oncology Bethanien, both in Frankfurt. read more
Prof. Loibl is internationally renowned in the fields of neoadjuvant breast cancer, breast cancer during pregnancy, and breast cancer in young women. She developed the translational research division within the GBG and has led numerous translational projects as well as research projects funded by the European Union Commission. She has led and participated in more than 100 national and international clinical trials in the field of breast cancer.
In 2014, she joined the Executive Board of the Breast International Group (BIG). As a medical expert, she serves on several international steering committees, translational research committees, and independent data monitoring committees.
Prof. Loibl has co-authored almost 300 Medline-listed scientific papers, in addition to more than 200 original and peer-reviewed articles and 30 books or book chapters. She has also actively contributed to more than 200 national and international congresses. She is an active member of numerous national and international organizations such as the American Society of Clinical Oncology and European Society of Medical Oncology.
Disclosures:
Grant/research support from Abbvie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Immunomedics, Novartis, Pfizer and Roche; Consultant/advisory board fees from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eli Lilly, Immunomedics, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Puma Biotechnology, Roche, Seagen and Samsung; Speaker bureau fees from AbbVie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Roche, Seagen and Samsung; Other Chugai Pharmaceutical Co.
Overview & Learning Objectives
Overview
In this activity, experts in HER2-positive breast cancer discuss the rationale and evidence for recently approved and emerging novel therapies and their potential impact in the management of patients with HER2-positive advanced breast cancer.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
Target audience
This activity has been designed to meet the educational needs of oncologists involved in the management of patients with breast cancer.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Faculty
Dr Eva Ciruelos discloses: Consultant/advisory board fees and congress assistance from Eli Lilly, Novartis, Pfizer and Roche.
Prof. Rupert Bartsch discloses: Grant/research support from Daiichi Sankyo, Novartis and Roche; Honoraria from Accord Healthcare, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Novartis, Pfizer, Roche and Sandoz; Advisory Board fees from AstraZeneca, Celgene; Daiichi Sankyo, Eisai, Eli Lilly, MSD, Novartis, Roche and Samsung.
Prof. Sibylle Loibl discloses: Grant/research support from Abbvie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Immunomedics, Novartis, Pfizer and Roche; Consultant/advisory board fees from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eli Lilly, Immunomedics, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Puma Biotechnology, Roche, Seagen and Samsung; Speaker bureau fees from AbbVie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Roche, Seagen and Samsung; Other Chugai Pharmaceutical Co.
Content Reviewer
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Date of original release: 14 December. Date credits expire: 14 December.
Learning Objectives
After watching this activity, you should be able to:
- Outline the rationale for novel treatment options for HER2-positive advanced breast cancer
- Recall the clinical data for emerging later-line treatment options for patients with HER2-positive advanced breast cancer
- Describe how novel treatment options may impact future management and address unmet needs in patients with HER2-positive breast cancer